Monitor the proxy contest outcome; if dissidents win seats, pressure for a sale process likely increases. Also watch whether the board engages with the acquisition proposals (May 14th offer expires May 29). The stock could trade closer to the offer price if a deal appears more probable.
Price Chart
Executive Summary
Activist group Radoff-JEC (7.8% owner) filed preliminary proxy statement to elect three director nominees to Seer's board at the 2026 annual meeting, citing severe value destruction (stock down ~97% since IPO, cumulative losses >$465M, Q1 revenue -34% YoY to $2.8M with $15.7M cash burn, market cap $92.4M vs $219.5M cash). The group previously made three non-binding acquisition proposals (latest $2.40/share + CVR, 42% premium) which the board rejected without engagement. The filing also seeks a 'no' vote on say-on-pay and against ratifying the poison pill adopted after the 13D filing.
Key Facts
- Radoff-JEC Group (7.8% owner) nominating three directors: Howard H. Berman (Ph.D., biotech CEO), Joshua S. Horowitz (portfolio manager/board member), Luis E. Rinaldini (investment banker)
- Submitted three non-binding all-cash acquisition proposals at $2.25, $2.35, and $2.40 per share plus CVR (42% premium to unaffected price), all expired without board engagement
- Q1 2026 revenue $2.8M, -34% YoY; cash burn $15.7M in quarter; $219.5M cash vs $92.4M market cap
- Cumulative net losses >$465M; CEO total compensation >$24.9M (2021-2024); CEO sold >$103M in stock since IPO
- Board adopted NOL poison pill 6 days after initial 13D, later amended after legal challenge (paid $250K mootness fee)
- Incumbent board faces plurality election; three dissident nominees would constitute a minority if elected
Financial Impact
Multiple takeover proposals at $2.40/share (42% premium) imply an equity value ~$132M, well above current market cap of $92M
Risk Factors
- Dissident nominees would be a minority of the board (3 of 7) and may not force a sale or strategic change
- Board's rejection of prior proposals suggests resistance to deal; dissidents may need to escalate or wage a longer campaign
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREC14A Filing (Primary) | 0000921895-26-001469 |
| Document: 0000921895-26-001469-index-headers.html | 0000921895-26-001469 |
| Document: 0000921895-26-001469-index.html | 0000921895-26-001469 |
| Document: 0000921895-26-001469.txt | 0000921895-26-001469 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | Press Release | $1.97 | awaiting T+20 | — | $1.96 (−0.51%) |
Oct 15, 2026 13d ago | ITC Section 337 | $2.03 | awaiting T+20 | — | $1.96 (−3.45%) |
Oct 8, 2026 19d ago | 3 | $2.19 | awaiting T+20 | — | $1.96 (−10.50%) |
Sep 21, 2026 5w ago | Press Release | $1.86 $2.02 | ▲ +8.60% | ▲ +9.51% | $1.96 (+5.38%) |
Jul 31, 2026 12w ago | 8-K | $2.22 $1.98 | ▼ −10.81% | ▼ −13.80% | $1.96 (−11.71%) |
Jul 28, 2026 13w ago | Press Release | $2.08 $2.02 | ▲ +2.88% | ▲ +7.90% | $1.96 (+5.77%) |
Jul 28, 2026 13w ago | DFAN14A | $2.14 $2.04 | ▼ −4.67% | ▼ −8.05% | $1.96 (−8.41%) |
Jul 20, 2026 14w ago | DEFA14A | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.96 (−3.92%) |
Jul 20, 2026 14w ago | Press Release | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.96 (−3.92%) |
Jul 8, 2026 15w ago | DEFA14A | $2.18 $2.19 | ▲ +0.46% | ▼ −2.81% | $1.96 (−10.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers